Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
The last decades have seen a major gain in understanding the action of cannabinoids and the endocannabinoid system in reward processing and the development of addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol and synthetic cannabinoids directly interact with the reward system and thereby have addictive properties. Cannabinoids induce their reinforcing properties by an increase in tonic dopamine levels through a cannabinoid type 1 (CB1) receptor–dependent mechanism within the ventral tegmental area. Cues that are conditioned to cannabis smoking can induce drug-seeking responses (ie, craving) by eliciting phasic dopamine events. A dopamine-independent mechanism involved in drug-seeking responses involves an endocannabinoid/glutamate interaction within the corticostriatal part of the reward system. In conclusion, pharmacological blockade of endocannabinoid signaling should lead to a reduction in drug craving and subsequently should reduce relapse behavior in addicted individuals. Indeed, there is increasing preclinical evidence that targeting the endocannabinoid system reduces craving and relapse, and allosteric modulators at CB1 receptors and fatty acid amide hydrolase inhibitors are in clinical development for cannabis use disorder. Cannabidiol, which mainly acts on CB1 and CB2 receptors, is currently being tested in patients with alcohol use disorder and opioid use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The EC system contributes to the reinforcing effects of all three substances, and undergoes changes following adolescent exposure to them [255].”
From Consequences of adolescent drug use (2023) · cites this paper as [255]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Crystal structures of agonist-bound human cannabinoid receptor CB1
Hua, T., Vemuri, K., Nikas, S. P., Laprairie, R. B., Wu, Y., Qu, L., Pu, M., Korde, A., Jiang, S., Ho, J.-H., et al. (2017) · Nature · doi:10.1038/nature23272 · Cited by 479
RetractedMolecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Spanagel, R., Herz, A., & Shippenberg, T. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2046 · Cited by 1,014
Self-citationElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.01.004 · Cited by 995
The dopamine hypothesis of reward: past and current status
Spanagel, R., & Weiss, F. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01447-2 · Cited by 973
Self-citation
Research works printed but not linked: 2
- Peters KZ, 2020, Cold Spring Harb Perspect Med, 21, a03930
- Zimmermann US, 2009, Dtsch Arztebl Int, 106, 464
Cited by
Consequences of adolescent drug use
Steinfeld, M. R., & Torregrossa, M. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02590-4 · Cited by 237
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Hasbi, A., Madras, B. K., & George, S. R. (2023) · Brain Sciences · doi:10.3390/brainsci13020325 · Cited by 79
“spiny neurons (D1-MSNs) (reviewed in [62]).”
BackgroundInfluentialThe Impact of Cannabidiol on Human Brain Function: A Systematic Review
Batalla, A., Bos, J., Postma, A., & Bossong, M. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618184 · Cited by 80
“…promising effects of CBD on reducing craving, negative affect and motivation for substance use (Chye et al., 2019; Hurd et al., 2019; Freeman et al., 2020; Spanagel, 2020), phenomena associated with fronto-striatal and limbic network disbalances (Koob and Volkow, 2016; Volkow and Boyle, 2018).”
BackgroundChronic Pain and Psychiatric Conditions
Johnston, K. J. A., & Huckins, L. M. (2022) · Complex Psychiatry · doi:10.1159/000527041 · Cited by 87
“The ECS also plays a role in nociceptive signaling and chronic pain [309–312], again involving dopamine transmission and reward circuitry in the brain [312, 313], in addition to being highlighted as a potential therapeutic target in ADHD [299, 314–316].”
BackgroundCannabidiol in the context of substance use disorder treatment: A systematic review
Paulus, V., Billieux, J., Benyamina, A., & Karila, L. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107360 · Cited by 58
Metadata
- Authors
- Spanagel, R.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Spanagel, Rainer
- ORCID
- Spanagel, Rainer
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2020-09-30
- Volume
- 22
- Issue
- 3
- Pages
- 241-250
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC7605022
- OpenAlex
- W3105701481
- Cited by
- 127
- References
- 72
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 29 · 2023: 26 · 2022: 18 · 2021: 10 · 2020: 1
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabinoids, endocannabinoid system, reward processing, addiction, cannabis use disorder, delta-9-tetrahydrocannabinol, synthetic cannabinoids, CB1 receptor, dopamine, ventral tegmental area, drug craving, relapse, corticostriatal pathway, fatty acid amide hydrolase inhibitors, allosteric modulators, cannabidiol, alcoholism, opioid use disorder
- MeSH terms
- Animals, Cannabinoids, Marijuana Abuse, Humans, Reward, Behavior, Addictive, Receptors, Cannabinoid, Drug-Seeking Behavior, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. https://app.cochat.ai/papers/10.31887/dcns.2020.22.3/rspanagel
- The paper
- Spanagel, R. (2020). Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2020.22.3/rspanagel
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.